Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs

Idiopathic pulmonary fibrosis (IPF) is a rare, chronic and ultimately fatal disease for which only palliative treatments existed until recently. Between 2011 and 2015, two new drugs, pirfenidone and nintedanib, were approved in the US and Europe for the treatment of IPF, providing hope for patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Audibert, Céline, Livoti, Christine, Caze, Alexis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935841/
https://www.ncbi.nlm.nih.gov/pubmed/29736460
http://dx.doi.org/10.1016/j.conctc.2016.04.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935841/
https://www.ncbi.nlm.nih.gov/pubmed/29736460
http://dx.doi.org/10.1016/j.conctc.2016.04.008

Ejemplares similares